document

C.V. - Robert D. Toto, M.D.

CURRICULUM VITAE

NAME: ROBERT D. TOTO, M.D.

ADDRESS: Department of MedicineDivision of NephrologyUT Southwestern Medical Center at Dallas5323 Harry Hines Blvd.Dallas, Texas 75390-8856TEL: 214 648-3482FAX: 214 648-2071Email: [email protected]

EDUCATION:

Medical Education:

1973-1977 University of Illinois Abraham Lincoln School of Medicine; Chicago, Illinois; M.D.

Undergraduate Education:

1970-1973 University of Wisconsin; Parkside Campus, Kenosha, WI

POSTDOCTORAL TRAINING:

1982-1983 Nephrology Postdoctoral Fellowship; UT Southwestern Medical Center; Dallas, Texas. Director: Juha P. Kokko, M.D., Ph.D.

1980-1981 Nephrology Postdoctoral Fellowship; U.S. Public Health Service Hospital; San Francisco, CA. Director: Henry N. Hulter, M.D.

1979-1980 Medical Resident; Baylor College of Medicine; Houston, TX. Director: Antonio Gotto, M.D.

1977-1979 Intern and Medical Resident (Internal Medicine); University of Michigan; Ann Director: William N. Kelley, M.D.

CURRENT POSITIONS:

The University of Texas Southwestern Medical Center at Dallas:Mary M. Conroy Professor of Kidney DiseaseProfessor of MedicineDirector of Patient-Oriented-Research in NephrologyDirector of Clinical Nephrology

1


ACADEMIC APPOINTMENTS:

2000-Present Professor with Tenure, Department of Medicine UT Southwestern Medical Center

1999 –2000 Clinical Professor of Medicine UT Southwestern Medical Center (20% time)1998-1999 Clinical Professor of Medicine UT Southwestern Medical Center at Dallas, Dallas,

Texas 1997-1998 Professor with Tenure Department of Internal Medicine, Clinical Director of

Nephrology Vanderbilt University Medical Center Nashville, TN1995-1997 Professor with Tenure Department of Internal Medicine; University of Texas

Southwestern Medical Center, Dallas, Texas1989-1995 Associate Professor; Department of Internal Medicine; University of Texas

Southwestern Medical Center, Dallas, Texas1983-1989 Assistant Professor; Department of Internal Medicine; University of Texas

Southwestern Medical Center, Dallas, Texas1985-1997 Director, Clinical Nephrology; UT Southwestern Medical Center, Dallas, Texas1986-1987 Acting Chief Division of Nephrology; UT Southwestern Medical Center at

Dallas1987-1997 Internal Medicine Housestaff Counselor; UT Southwestern Medical Center at

Dallas

OTHER RELEVANT PROFESSIONAL EXPERIENCE:

1998-2000 Director, Clinical Research Institute, Dallas Nephrology AssociatesPrivate Practice in Nephrology, Dallas Nephrology Associates

HOSPITAL APPOINTMENTS:

1998-Present Attending Physician, Department of Medicine, UT Southwestern Medical Center Dallas Parkland Memorial and Zale-Lipshy Hospitals, Dallas, TX

1998-Present Chief of Nephrology, Methodist Medical Center Dallas, TX1997-1998 Attending Physician, Department of Medicine, Vanderbilt University Nashville, TN1983-1997 Attending Physician, Department of Medicine UT Southwestern Medical Center Dallas,

Parkland Memorial and Zale-Lipshy Hospitals, Dallas, TX

MEDICAL DIRECTORSHIPS:

1997-1998 Medical Director, Middle Tennessee Dialysis Clinics Nashville, TN1986-1994 Medical Director, Chronic Dialysis Unit Parkland Memorial Hospital, Dallas, TX1987-1997 Medical Director, Acute Dialysis Unit, Parkland Memorial Hospital, Dallas, TX2001-present Medical Director, Parkland Health and Hospitals Renal Clinic2001-present Medical Director, Acute Dialysis Unit, Parkland Memorial Hospital, Dallas, TX

2


HONORS & AWARDS:

1977 Alpha Omega Alpha Medical Honor Society1987 Outstanding Teacher Award, Internal Medicine Housestaff, UT Southwestern Medical Center1992 Outstanding Teacher Award, Medical Student Class of 1995, UT Southwestern Medical Center1993 Outstanding Teacher Award, Medical Student Class of 1996, UT Southwestern Medical Center1994 Outstanding Teacher Award, Medical Student Class of 1997, UT Southwestern Medical Center1995 Outstanding Teacher Award, Medical Student Class of 1998, UT Southwestern Medical Center1995 Fellow High Blood Pressure Council of The American Heart Association1996 Outstanding Teacher Award, Medical Student Class of 1999, UT Southwestern Medical Center1997 Outstanding Teacher Award, Medical Student Class 2000, UT Southwestern Medical Center

LICENSURE:

Texas: January, 1980 # F5779Tennessee: April, 1997 # 21857

BOARD CERTIFICATION:

September, 1980 American Board of Internal MedicineNovember, 1982 American Board of Internal Medicine Subspecialty, NephrologyNovember, 1987 American Board of Internal Medicine Subspecialty, Critical Care MedicineNovember, 1997 American Board of Internal Medicine Subspecialty, Critical Care Medicine Re-

certification

MAJOR COMMITTEE ASSIGNMENTS:

2004-present Heme-Onc Chief Search Committee UT Southwestern at Dallas2001-2003 Medical School Curriculum Committee at UT Southwestern at Dallas 2001-2000 Medical School Promotions Committee at UT Southwestern at Dallas1990-1997 General Clinical Research Center Executive Committee, UT Southwestern 2000-present Medical Center at Dallas1990-1997 Admissions Committee, UT Southwestern Medical School 1992-1997 Special Care Units Committee, Zale-Lipshy University Medical Center1992-1997 Committee to Evaluate Clinical Competence, Department of Medicine,

UT Southwestern Medical Center1989-1997 Chiefs of Service Committee, Parkland Memorial Hospital1997 President-Elect of the Medical Staff, Parkland Hospital 1990-1997 Credentials Committee Zale-Lipshy University Medical Center Hospital 1994-1995 Physician Survey Committee, Parkland Memorial Hospital 1994-1997 Long-term Planning Committee, Outpatient Clinic, Parkland Memorial

Hospital 1991 Search Committee for Vice President for Clinical Affairs UT

Southwestern Medical Center at Dallas

3


EDITORIAL BOARDS AND GRANT REVIEW COMMITTEES:

2005 Chairman, Special Emphasis Panel on Chronic Kidney Disease NIH/NIDDK2004 Special Emphasis Panel on Diseases of the Kidney NIH/NIDDK2001-2005 Journal of American Society of Nephrology 1994-1998 Kidney International 1996-2001 American Journal of Kidney Diseases 1999-Present Section Editor, Current Opinion in Nephrology and Hypertension 1997-2005 Section Editor, Nephrology, Dialysis and Transplantation 1998-Present American Journal of Nephrology 1994, 1996, 1999, 2002 Reviewer, Special Study Sections, NIH-NIDDK/KHUD 1991-1996 Texas American Heart Association Grant-in-Aid Review Committee 1990, 1993 Ad Hoc Reviewer VA Merit Review Study Section

MANUSCRIPT REVIEWER FOR OTHER SCIENTIFIC JOURNALS:

American Journal of Physiology: Renal, Fluid and ElectrolyteAnnals of Internal MedicineCirculationDiabetesJournal of the American Medical AssociationJournal of the American Society of NephrologyJournal of Diabetic ComplicationsHypertensionMetabolism

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

American Society of NephrologyAmerican Federation for Clinical ResearchAmerican Association for Advancement of ScienceAmerican Heart Association, Kidney CouncilAmerican Heart Association, High Blood Pressure CouncilInternational Society of NephrologyAmerican Physiological SocietyRenal Physicians Association American Society of HypertensionAssociation of Clinical Research Training Program (K30) DirectorsNational Kidney Foundation

4


MAJOR COMMITTEE ASSIGNMENTS AND OTHER EXPERIENCE IN PROFESSIONAL SOCIETIES:

American Society of NephrologyInvited Speaker Clinical Nephrology Course on Ischemic Nephropathy San Diego, CA 2003Invited speaker ASN Postgraduate Course on Cardiovascular Disease in Patients with Chronic Kidney Disease, San Diego, CA 2003. Invited speaker ASN Postgraduate Course on Cardiovascular Disease in Patients with Chronic Kidney Disease, Philadelphia PA 2002. Editorial Board, Journal of American Society of Nephrology 2001-presentMember Nominating Committee 2001Clinical Science Committee 2001-2003Abstract Reviewer, Dialysis Section, Annual Meeting San Francisco, CA 2001Invited Speaker: Literature Review: Ischemic Nephropathy, Annual Meeting Toronto 2000Scientific Program Committee Annual Meeting 1999, Clinical Nephrology Expert ASN "Fly-In" Program June 1999. Discussions on Capitol Hill with Texas Senators and Representatives: NIH Funding for Fiscal 2000 and beyondLecturer, Board Review Course in Nephrology, San Francisco, CA 1999Lecturer, Board Review Course in Nephrology, San Francisco, CA 1998Abstract Reviewer, Acute Renal Failure: (Basic), Annual Meeting Philadelphia, PA 1998Invited Speaker: Clinical Science Symposium on Hypertensive Renal Disease, 1997Invited Speaker: Clinical Science Symposium "Treatment of Rapidly Progressive Glomerulonephritis", San Diego, CA 1995Invited Speaker: Chairperson Short Course in Nephrology "Fluid and Acid-Base Disorders in the ICU". San Diego, CA 1995Scientific Program Committee Annual Meeting 1994, Dialysis Expert Abstract Reviewer, Clinical Nephrology, Annual Meeting Orlando, FL 1994Invited Speaker: "Clinicopathological Correlations in Glomerular Disease", Boston, MA. 1993Abstract Reviewer, Clinical Nephrology, Annual meeting Boston, MA 1993Invited Speaker: Mini-lecture: "Renal Insufficiency Due to ACE Inhibitors" Baltimore MD 1992Abstract Reviewer, Acid-Base Disorders, Annual Meeting Washington, DC 1991

National Kidney Foundation Chairman, Scientific Advisory Board National Kidney Foundation of North Texas, 2003-presentMember, Board of National Kidney Foundation of North Texas 2003-presentMember Scientific Advisory Committee National Kidney Foundation 2003- presentMember, Committee on Proteinuria in Renal Disease (PARADE) March 1998Invited Speaker: National Kidney Foundation Annual Clinical Nephrology Meeting Chicago, IL, “Who Should Not Receive An ACEI or ARB With Chronic Renal Disease” “Clinical Trials Update: Primary results of the AASK Trial”, Chicago, IL 2002Invited Speaker: National Kidney Foundation Annual Meeting Clinical Science Symposium"When to Initiate Dialysis and How Much Is Enough", New Orleans, LA 1996Invited Speaker: National Kidney Foundation of Texas Symposium on Renal Diseases "Resistant Forms of Hypertension", Lubbock, TX 1996Invited Speaker: National Kidney Foundation of Texas "Role of Lipids in Progressive Renal Disease", Houston, TX 1995

5


Invited Speaker: National Kidney Foundation, Orlando, FL "Treatment of Dyslipidemia in Diabetic Nephropathy" 1994Invited Speaker: National Kidney Foundation of Texas "Nutrition in patients with End-Stage Renal Disease" Dallas, TX 1994Chairman, Clinicopathological Conference National Kidney Foundation Spring Clinical Meeting April 1997

International Society of Nephrology

Clinical Nephrology and Dialysis Subcommittee, Buenos Aires, Argentina 1999, ChairInvited Speaker: International Society of Nephrology Meeting Madrid, Spain Symposium on New Clinical Trials in Nephrology "Results from the AASK Pilot Study" 1995Chairman, Continuing Medical Education Course (English version) Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999, 1997-1999Chairman, Dialysis Section Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999, 1997-1999

VISITING PROFESSOR ACTIVITIES:

University of California at San Francisco, San Francisco, CA Renal Division, October 1990University of Alabama, Birmingham, AL Renal Division, October 1991University of Oklahoma, Oklahoma City, OK Renal Division, July 1992University of Texas at Houston, Houston, TX Renal Division, December 1992Ohio State University, Dept. of Medicine and Renal Division, Columbus, OH, March 1993Vanderbilt University, Dept. of Medicine and Renal Division, Nashville, TN, December 1993Brook Army Medical Center, San Antonio, TX, February 1994University of Colorado Health Science Center Division of Nephrology, April 1995University Medical and Dental School of New Jersey Medical Center-Robert Wood Johnson Department of Medicine and Division of Nephrology, December 1995 University of Florida at Gainesville, Division of Nephrology and Department of Medicine, January 1996University of Texas at San Antonio, Division of Nephrology, April 1996Duke University Medical Center, February 19-20th 1998University of Alabama Medical Center at Birmingham, June 4-6th, 1998University of Indiana at Indianapolis, September 29-Oct 1, 1998Wayne State University, Detroit MI, June 1-2, 1999Duke University, Division of Nephrology, February 2002University of California Irvine, Nephrology Division, June 2003University of Michigan Medical School, Nephrology Division, December 2003Yale University Medical Center Nephrology Division, December 2003University of Colorado Denver, Colorado Nephrology Division, March 2004University of Washington Seattle, Washington Nephrology Division, September 2004Massachusetts General Hospital Medical Grand Rounds, September 2004Emory University Atlanta Georgia Renal Grand Rounds, October 2004

6


ADVISING RESPONSIBILITIES:

1993-1994Advisory Panel, UT Southwestern Medical Center Curriculum Committee Advisor, 4th Year Medical Students, Department of Internal Medicine, UT Southwestern Medical 1989-1997Center at Dallas 1986-1997Housestaff Counselor, Department of Internal Medicine, UT Southwestern Medical Center at Dallas 2000-2001 Advisor/Counselor, UT Southwestern Department of Internal Medicine Intern 2000-present Advisor Senior Medical Students UT Southwestern Medical Center

REGIONAL, NATIONAL AND INTERNATIONAL CONTRIBUTIONS:

Invited Presentations:2004 First International Conference on Albuminuria NY, NY. “Proteinuria in African-Americans”2004 National Kidney Foundation National Meeting Chicago, IL “Hypertensive Nephrosclerosis”2004 American Society of Nephrology National Meeting November 2004 St. Louis “Is there a drug

for preserving kidney function in Hypertension?”2004 American Heart Association National Conference New Orleans November. “Chronobiology of

Blood Pressure-How to achieve Blood Pressure Goals”2004 Italian Society of Nephrology Ischia, Italy October, “Heart Disease in Diabetes“2004 UTSW Internal Medicine Update Galleria Hotel Dallas. November. “Diabetic Nephropathy2004 Primary Care Symposium Chicago IL. June. “Special Considerations in the Management of

Diabetic Hypertension”2003 National Kidney Foundation Clinical Nephrology Meeting Dallas, TX April “Blood pressure in

chronic kidney disease: How low should you go?” 2003 American Diabetes Association “Dyslipidemia in Renal Disease Treatment” New Orleans, LA

June.2003 American Heart Association Plenary Session “May we AASK is there a special medication for

lowering blood pressure in chronic kidney disease” Orlando, FL. November 2002 National Kidney Foundation Annual Clinical Nephrology Meeting Chicago, IL, “Who Should

Not Receive An ACEI or ARB With Chronic Renal Disease” “Clinical Trials Update: Primary results of the AASK Trial”

2001 American Society of Nephrology Annual Meeting San Francisco CA Clinical Science Symposium Update in Clinical Trials: “ Comparison of Relevant Megatrials in Nephrology”

2001 International Society of Hypertension in Blacks Las Vegas NV “Measurement of Renal Function in African Americans: Lessons from Clinical Trials”

2001 American College of Physicians Atlanta GA “Acid-Base, Hematuria and Proteinuria” seminar2001 Medical Grand Rounds University of Oklahoma City June 132001 Hypertension Board Review Course, American Society of Hypertension. Chicago, IL, March

22-232001 NIH sponsored conference on Research Career in Clinical Nephrology, Bethesda, MD2000 NIH sponsored conference on Research Career in Clinical Nephrology, Bethesda, MD2000 International Society of Hypertension Symposium on Chronic Renal Failure Chicago, IL

August 202000 International Symposium on Angiotensin II, Tokyo, Japan, "Role of AII receptor Antagonists

in Renal Disease"

7


1999 Southeastern Dialysis and Transplant Association, New Orleans, LA. "Prevention of Progressive Renal Disease"

1999 ESRD Network 14 Annual Meeting "Non-nutritional causes of hypoalbuminemia in renal disease"

1999 The Southwest Pediatric Nephrology Study Group and The National Kidney Foundation of Texas. "Mechanisms and specific renal diseases associated with proteinuria and the nephrotic syndrome", Medical City Dallas Hospital

1998 Geriatrics and Nephrology Retreat, Jasper Lodge Alberta, Canada. Sponsored by The Hartford Foundation

1998 University of Oklahoma Critical Care Board Review Course "Approach to the Patient with Non-Oliguric Acute Renal Failure", Oklahoma City, OK

1997 University of Oklahoma Critical Care Board Review Course "Approach to the Patient with Non-Oliguric Acute Renal Failure", Oklahoma City, OK

1996 Internationaliones Medico Institute Nephrologie IMIN, "When to Initiate Dialysis and How Much is Enough" and "Timely Issues in the Use of ACE Inhibitors in Nephrology", Huatulco, Mexico

1996 National Kidney Foundation Annual Meeting Clinical Science Symposium "When to Initiate Dialysis and How Much Is Enough", New Orleans, LA

1996 National Kidney Foundation of Texas Symposium on Renal Diseases "Resistant Forms of Hypertension", Lubbock, TX

1995 American Society of Nephrology Clinical Science Symposium "Treatment of Rapidly Progressive Glomerulonephritis", San Diego, CA

1995 National Kidney Foundation of Texas "Role of Lipids in Progressive Renal Disease", Houston, TX

1995 Baylor College of Medicine Endocrinology Grand Rounds, Houston, TX. Role of Angiotensin II receptor antagonists in Hypertension and Renal Disease

1995 Master of Ceremonies General Clinical Research Center Awards Ceremony UT Southwestern Medical Center at Dallas

1995 American Society of Nephrology Chairperson Short Course in Nephrology "Fluid and Acid-Base Disorders in the ICU". San Diego, CA

1995 International Society of Nephrology Meeting Madrid, Spain Symposium on New Clinical Trials in Nephrology "Results from the AASK Pilot Study"

1994 National Kidney Foundation, Orlando, FL "Treatment of Dyslipidemia in Diabetic Nephropathy"

1994 Symposium on Clinical Research Careers "Bench-to-Bedside Collaborations" Department of Clinical Nutrition UT Southwestern Medical Center, Dallas

1994 International Society of Blood Purification. Maastrict, The Netherlands "Treatment of Dyslipidemia in Renal Failure"

1994 International Society for Hypertension in Blacks. Cleveland, OH "The Progression of Renal Disease in Hypertensive Nephrosclerosis in Blacks"

1994 National Kidney Foundation of Texas "Nutrition in patients with End-Stage Renal Disease" Dallas, TX

1993 American Society of Nephrology Boston, MA. "Clinicopathological Correlations in Glomerular Disease"

1992 American Society of Nephrology Baltimore MD. "Renal Insufficiency Due to ACE Inhibitors"1992 Invited Speaker: International Society for Advances in Prostaglandins, Thromboxane and

Leukotriene Research, Florence, Italy "Role of Synthetic PGE1 analogues in Renal Disease"

8


PROFESSIONAL LEADERSHIP ROLES RELATED TO TEACHING AND RESEARCH:

2004 Organizing Committee and Faculty Member Bethesda MD, July. NIH-sponsored “Clinical Research in Kidney and Urologic Disease”

2002-present Program Director Training Program in Patient Oriented Research UT Southwestern2002-present Program Director Annual Symposium on Techniques of Patient Oriented Research

2002 Member, NIH Task force on Clinical Trials, NIDDK, March 7-8, 2001, Washington

2001 American Society of Nephrology Abstract Reviewer Dialysis Section2001 Chairman, Guidelines for Renal Biopsy Committee of The National Kidney

Foundation Kidney and Dialysis Outcomes Quality Initiative2001 Chairman, NIH planning committee on Preparing for Career in Clinical

Research Career in Nephrology for 2001 meeting in Washington DC 2000 Member, NIH planning committee on Preparing for Career in Clinical Research

Career in Nephrology September 9-10, 2000 Bethesda MD1999-2000 Chairman, Physicians Advisory Board Spectra Renal Research1999 Lecturer, American Society of Nephrology Board Review Course in

Nephrology September 1998 San Francisco, CA1998 Lecturer, ASN Board Review Course in Nephrology September 1998 San

Francisco, CA1998 Abstract Reviewer on Acute Renal Failure (Basic Science), American Society of

Nephrology, Annual Meeting in Philadelphia, PA1999 Chairman, Clinicopathological Conference National Kidney Foundation Spring

Clinical Meeting April 19971997-1999 Chairman, Continuing Medical Education Course (English version) Scientific Program

Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999

1997-1999 Chairman, Dialysis Section Scientific Program Committee for the International Society of Nephrology Meeting in Buenos Aires in 1999

1996-1998 Member, Writing Committee for Medical Self-Knowledge Assessment Program, Subspecialty in Nephrology American College of Physicians

1994 Abstract Reviewer, Clinical Nephrology, American Society of Nephrology, Annual Meeting in Orlando, FL

1993 Abstract Reviewer, Clinical Nephrology American Society of Nephrology Annual meeting in Boston, MA

1993-1995 Coordinator UT Southwestern Internal Medicine Board Review Course Renal Section, Dallas, Texas

1990 Abstract Reviewer, American Society of Nephrology Annual Meeting, Washington, DC

2000 NIH sponsored "Preparing for a Research Career in Clinical Nephrology"

9


MAJOR RESEARCH INTERESTS:

Mechanisms, Risk Factors and Treatment of Progressive Forms of Chronic Renal DiseasesDiabetic Nephropathy: Pathogenesis, Progression and Prevention Hypertensive Nephrosclerosis Mechanism, Diagnosis and Clinical ManagementDialysis Adequacy and Outcome in patients with End-Stage Renal DiseasePathophysiology, Metabolism and Clinical Consequences of abnormal plasma lipoproteins in Chronic

Renal FailureCost-Effectiveness of Renal Health Care DeliveryOutcomes Research in NephrologyRenal Epidemiology

GRANT SUPPORT:

FEDERAL

ActiveNIH Title of Project: African-American Study of Kidney Disease and Hypertension (AASK) – Cohort Study, July 1, 2002 - June 30, 2007Total Award $2,195,000 Role on Project: Co-Investigator

NIHTitle of Project: Mentoring Program for Clinical Researchers in Nephrology May 2001 – April 2006Total award $ 579,056Role on Project: Principal Investigator

NIHTitle of Project: Improving Outcomes in Diabetic NephropathyOctober 1, 2002-Sept 30, 2004Total Award: 1,000,000Role on Project: Principal Investigator

NIHTitle of Project: Curriculum in Clinical Research AwardJuly 1999-June 2005Total Award: 1,000,000Role on Project: Principal Investigator

NIHTitle of Project: Cardiovascular Outcomes in Renal Artery Lesions (CORAL)April 2004-March 2009Total Award: 75,000Role on Project: Co-Investigator

10


NON-FEDERAL

Current:

Grantor: Eli Lilly and Co.Title: The Effect of LY333531 on Diabetic Proteinuria: A Pilot Clinical TrialJune 1, 2002-May 30, 2003Amount of Award: $62,000Role on Project: Principal Investigator

Grantor: Oxford Study GroupTitle: Study of Heart and Renal Protection (SHARP)Jan 15, 2005-Dec 31 2008Amount of Award 200,000Role on Project: Principal Investigator Dallas Center

Past:

Grantor: NIH 1 UO1 DK 453386-01 Title of Project: African-American Study of Kidney Disease and Hypertension, Pilot Study July 1992-June 1994Total Award: $343,087Role: Principal Investigator

Grantor: NIH 1 U01 DK453386-01 Title of Project: African-American Study of Kidney Disease and Hypertension (AASK) - Full scale trial, July 1, 1994 - June 30, 2001. Total Award $3,604,267Role: Principal Investigator

Grantor: NIH R-23 DK 155362-03Title of Project: Role of cytochrome P450 Metabolites of Arachidonic Acid in renal function Total Amount of Award and Dates: 1985-1988, $105, 000Role: Principal Investigator

Non-NIH

Grantor: Bayer PharmaceuticalsTitle of Project: Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival May 2000-April 2002Total Award: $234,000Role on Project: Principal Investigator

Grantor: Bristol Myers Squibb

11


Title of Project: The Effect of Irbesartan on Progression of Renal Disease in Type II Diabetics with Nephropathy October 1995-96Total Award $48,000Role: Principal Investigator

Grantor: Merck, Sharp and DohmeTitle of Project: The efficacy and safety of Losartan/Hydrochlorothiazide in patients with chronic renal insufficiency March 1994 - December 1995Total award $60,000Role: Principal Investigator

Grantor: Scios-NovaTitle of Project: A double-blind randomized, placebo-controlled, Phase II/III, Multicenter Clinical trial to evaluate the safety and efficacy of intravenous auriculin hANP in the treatment of acute tubular necrosis July 1994 - June 1995.Total award $86,087Role: Principal Investigator

Grantor: G.D. Searle Co. Title of Project: Effect of Enisoprost on progression of renal failure in rats Total amount of award and dates: $20,000, 1988-1989 Role: Principal Investigator

Grantor: G.D. Searle Co.Title of Project: Effect of Enisoprost on NSAID-induced renal insufficiency in chronic renal failure Total amount of award and dates: $98,000, 1988-1989Role: Principal Investigator

Grantor: Merck, Sharp and DohmeTitle of Project: Lipoprotein Metabolism in Diabetic NephropathyRole: Principal Investigator December 1992-December 1993Total Amount of Award: $15,000

Grantor: Merck, Sharp and DohmeTitle of Project: An Open, Multicenter Study to Evaluate the Safety, Tolerability, and Antihypertensive Efficacy of Losartan in Patients with Hypertension Associated with Renal Impairment December 1992-December 1993Total Amount of Award and dates: $42,000 Role: Principal Investigator

Grantor: Merck, Sharp and Dohme Title of Project: Control of Renal disease progression by enalapril in hypertensive nephrosclerosis July 1988-December 1991Total Amount of Award $479,000Role: Principal Investigator

12


PUBLICATIONS:

Original Articles:

1. Hulter HN, Toto RD, Banner EL Jr., Ilnicki LP, Sebastian A. Renal and systemic acid-base effects of chronic hypoparathyroidism in dogs. Am J Physiol 241 (Renal Fluid Electrolyte Physiol 10):F495-F501, 1981

2. Hulter HN, Sebastian A, Toto RD, Banner EL Jr., Ilnicki LP. Renal and systemic acid-base effects of chronic administration of hypercalcemia-producing agents: Calcitriol, PTH, and intravenous Ca++. Kidney Int 21:445-458, 1982

3. Hulter HN, Toto RD, Ilnicki LP, Sebastian A. Chronic hyperkalemic renal tubular acidosis induced by KCl loading. Am J Physiol 244 (Renal Fluid Electrolyte Physiol 13): F255-F264, 1983

4. Hulter HN, Toto RD, Ilnicki LP, Halloran B, Sebastian A. Metabolic alkalosis in models of primary and secondary hyperparathyroid states. Am J Physiol 245 (Renal Fluid Electrolyte Physiol. 14):F450-F461, 1983

5. Hulter HN, Gustafson LE, Bonner EL Jr., Toto RD, Mackie S. Thyroid replacement in thyroparathyroidectomized dogs. Miner Electrolyte Metab 10(4):228-232, 1984

6. Toto RD, Hulter HN, Sebastian A. Renal tubular acidosis induced by dietary chloride. Kidney Int 25:26-32, 1984

7. Hulter HN, Toto RD, Sebastian AS, Mackie S, Cooke CR, Wilson TE. Effect of extracellular fluid volume depletion on renal regulation of acid-base and potassium equilibrium during prolonged mineral acid administration. J Lab Clin Med 103(6): 854-862, 1984

8. Hulter HN, Halloran BP, Toto RD, Peterson JC. Long-term control of plasma calcitriol concentration in dog and human: Dominant role of plasma calcium concentration in experimental hyperparathyroidism. J Clin Invest 76:695-702, 1985

9. Brater DC, Anderson SA, Brown-Cartwright D, Toto RD, Chen A, Jacob GB. Effect of etodolac in patients with moderate renal impairment compared with normal subjects. Clin Pharmacol Ther 38(6):674-679, 1985

10. Baum M, Toto RD. Lack of a direct effect of atrial natriuretic factor in the rabbit proximal tubule. Am J Physiol 250:(Renal, Fluid Electrolyte Physiol 19): F66-F69, 1986

11. Toto RD, Anderson SA, Brown-Cartwright D, Kokko JP, Brater DC. Effects of acute and chronic dosing of nonsteroidal anti-inflammatory drugs in patients with renal insufficiency. Kidney Int 30:760-768, 1986

12. Brater DC, Anderson SA, Brown-Cartwright D, Toto RD. Effects of nonsteroidal antiinflammatory drugs on renal function in patients with renal insufficiency and cirrhosis. Am J Kidney Dis 8:351-355, 1986

13


13. Toto RD, Siddhanta A, Manna S, Pramanik B, Falck JR, Capdevila J. Arachidonic acid epoxygenase: detection of epoxyeicosatrienoic acids (EETs) in human urine. Biochim et Biophys Acta 919:132-139, 1987

14. Helderman JH, Hernandez J, Sagalowsky A, Dawidson I, Glennie J, Womble D, Toto RD, Brinker K, Hull AR. Confirmation of the utility of fine needle aspiration biopsy of the renal allograft. Kidney Int 34(3):376-381, 1988

15. Hernandez JA, Glennie J, Toto RD, Sagalowsky A, Dawidson I, Helderman JH. A novel use of fine-needle aspiration biopsy: documentation of acute pyelonephritis of the transplanted kidney. Transplant Proc 20(4):632-4, 1988

16. Firth BG, Phil D, Perna R, Bellomo JF, Toto RD. Cardiorenal effects of atrial natriuretic factor administration in congestive heart failure: natriuresis and diuresis without hemodynamic alterations. Am J Med Sci 297:203-208, 1989

17. Dawidson IJA, Coorpender L, Fisher D, Helderman H, Hull A, Palmer B, Peters P, Sagalowsky A, Sandor ZF, Toto R, Reisch J. Impact of race on renal transplant outcome. Transplantation 49:63-67, 1990

18. Toto RD. Acute tubulointerstitial nephritis. Am J Med Sci 299:392-410, 1990

19. Toto RD. Role of prostaglandins in NSAID-induced renal dysfunction. Adv Prostaglandin Thromboxane Leukot Res 21B: 967-74, 1991

20. Toto RD, Mitchell HC, Milam C, Pettinger WA. Reversible renal insufficiency due to converting enzyme inhibitors in hypertensive nephrosclerosis. Annals Int Med 115:513-519, 1991

21. Palmer BF, Toto RD. Severe neurologic toxicity induced by cyclospine A in three renal transplant patients. Am J Kid Dis 18(1):116-121, 1991

22. Converse RL, Jabobson TN, Toto RD, Jost CM, Cosentino F, Tarazi F, Victor R. Sympathetic overactivity in patients with chronic renal failure. New Engl J Med 327:1912-1918, 1992

23. Arrambide K, Toto RD. In: Tumor Lysis Syndrome. Semin Nephrol 13: 273-280, 1992

24. Converse RL, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, Fouad-Tarazi F, Victor RD. Paradoxical withdrawal of reflect vasoconstriction as a cause of hemodialysis-induced hypertension. J Clin Invest 90: 1657-1665, 1993

25. Agarwal R, Toto RD. Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers Am. J. Kid. Dis. 22:296-99, 1993

26. Ahsan N, Palmer BF, Wheeler D, Greenlee R, Toto RD. Intravenous immunoglobulin induced osmotic nephrosis. Arch Intern Med 154:1985-7, 1994

27. Toto RD. Renal insufficiency due to ACE inhibitors. Miner Metab 20:193-200, 1994

14


28. Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoprotein in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 47:579-586, 1995

29. Toto RD, Mitchell HC, Lee H-C, Smith RD, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48(3): 851-859, 1995

30. Bankhead M, Toto RD, Star RA. Accuracy of urea removal estimated by kinetic models Kidney Int 48(3):785-793, 1995

31. Toto RD. Treatment of dyslipidemia in chronic renal failure. Blood Purif 14(1):75-82, 1996

32. Toto RD, Adams-Huet B, Fenves A, Mitchell HC, Mulcahey W, Smith RD. Effect of ramipril on blood pressure and protein excretion rate in normotensive non-diabetes with proteinuria Am J Kid Dis 28:832-840, 1996

33. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens. 4(6):505-509, 1995

34. Toto RD, Vuitch F. A non-compliant hemodialysis patient with severe secondary hyperparathyroidism. Semin Nephrol 9:424-427,1996

35. Wright JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, Randall OS, Glassock R. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 17:3S-16S, 1996

36. Toto RD, Kirk KA, Coresh J, Agodoa LY, Olutande B, Agodoa L. Evaluation of serum creatinine as an estimate of the glomerular filtration rate in African-Americans with hypertensive nephrosclerosis: Results for the African American Study of Kidney Disease and Hypertension (AASK Pilot Study). J Am Soc Nephrol 8(2): 279-287, 1997

37. Mitchell HC, Smith R, Cutler J, Sica D, O'Conner D, Toto RD. Racial differences in the renal response to blood pressure lowering during chronic angiotensin converting enzyme inhibition: A prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensives with mild to moderate renal insufficiency. Am J Kidney Dis 29(6): 897-906, 1997

38. Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S. Efficacy and tolerability of losartan in Patients with chronic renal insufficiency. Hypertension 31(2):684-91,1998

39. Coresh J; Toto RD; Kirk KA; Whelton PK; Massry S; Jones C; Agodoa L; Van Lente F. Creatinine clearance as a measure of GFR in screenees for the African- American Study of Kidney Disease and Hypertension pilot study. Am J Kidney Dis 32(1):32-42, 1998

40. Smith AC, Toto RD, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 54: 889-896, 1998

15


41. Toto RD, Vega GL, Grundy SM. Effect of Pravastatin on the metabolism of low-density lipoprotein in nephrotic dyslipidemia. Am J Nephrol I20:12-17, 2000

42. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am. J. Kid. Dis 36(3):646-661, 2000

43. Toto RD. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 25:161(12):1492-9, 2001

44. Elliott WJ, Maddy R, Toto R, Bakris G. Hypertension in patients with diabetes. Overcoming barriers to effective control. Postgrad Med 107(3):29-32, 35-6, 2000

45. Rosenthal D, Beccerra C, Toto RD, Carbone DP, Frenkel EP. Reversible renal toxicity resulting from high single-doses of the new radiosensitizer gadolinium texaphyrin. Am J Clin Onc 23(6):593-8, 2000

46. Jafar T, Schmid CH, Landa M, Giatras I, Lau J, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Levey A. Angiotensin-converting enzyme inhibitors and progression of disease. A meta-analysis of patient-level data. Ann Int Med 135(2)73-87, 2001

47. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, The Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001

48. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001

49. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER III, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285(21):2719-2728, 2001

50. Toto RD. Hypertension and kidney literature review. Clin Nephrol 58(4):253-259, 2002

51. Tuncel M, Augustyniak R, Zhang W, Toto RD, Victor RG. Sympathetic nervous system function in renal hypertension. Curr Hypertens Rep 4(3):229-236, 2002

52. Augustyniak R, Tuncel M, Zhang W, Toto RD, Victor RG. Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 20(1):3-9, 2002

16


53. Toto RD. Hypertension and the failing kidney. Curr Opin Nephrol Hypertens 10(2):165-166, 2001

54. Toto RD. Appropriate drug therapy for improving outcomes in diabetic nephropathy. Curr Diab Rep 2:545-552, 2002

55. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347(25):2010-9, 2002

56. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288(19):2421-31, 2002

57. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Bibeiro AB, Shahinfar S, Simpson RL, Snapinn SM and Toto R. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63(4):1499-507, 2003

58. Mohanram A, Toto RD. Outcome studies in diabetic nephropathy. Semin Nephrol 23(3):255-71, 2003

59. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, Marcantoni C, Becker G, Shahinfar S, De Jong PE, de Zeeuw D, Kamper AL, Strangaard S, Levy AS. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 18(10)2047-53, 2003

60. Kaysen GA, Greene T, Daugirdas JT, Kimmel PL, Schulman GW, Toto RD, Levin NW, Yan G; HEMO Study Group. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 42(6):1200-11, 2003

61. Toto RD. Hypertensive nephrosclerosis in African Americans. Kidney Int 64(6):2331-41, 2003

62. Toto RD. Anemia of chronic disease: past, present, and future. Kidney Int Suppl 87:S20-3, 2003

63. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42(4):617-22, 2003

64. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139(4):244-52, 2003

17

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14655192&dopt=Abstract

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14655192&dopt=Abstract


65. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23(5):307-14, 2003

66. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS; for the HEMO Study Group. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65(6):2380-9, 2004

67. Abosaif NY, Arije A, Atray NK, Baade KJ, Barboza JA, Basci A, Becker GJ, Bellorin-Font E, Beto JA, Bhaskaran M, Bilous R, Botev RC, Burchell K, Burden R, Burrowes JD, Byrd LH, Campese VM, Carroll LE, Charra B, Conley L, Depner TA, Dwyer J, Dy G, Fimian D, Finkelstein FO, Gagne S, Gargan C, Gates WH, Golper TA, Gonyea JE, Greene JH, Haley WE, Hartman J, Hogg RJ, Hogue ML, Hull AR, Jha V, Johnson RJ, Kadiroglu AK, Krause ES, Kurokawa K, Langman CB, Lerma E, Leunissen KM, Levin NW, Linus SJ, Locatelli F, London G, Makhuli M, Michael MA, Moist LM, Molitch ME, Mooty J, Morad Z, Mouratoff J, Nafar M, Narva AS, Nissenson AR, Obrador GT, Parekh R, Parra D, Patel TG, Payne G, Pizzarelli F, Prisant LM, Ranganna K, Reams SM, Riesland R, Ritz E, Roberts PJ, Rossert J, Saxena R, Scantlebury V, Schoolwerth AC, Segal P, Sheps SG, Sirenko Y, Spry LA, Stair GA, Steinman TI, Thavarajah S, Thorpe R, Toto RD, Tutor R, Tuttle KR, Van Wyck DB, Vanholder R, Vassalotti J, Walker R, Wang H, Wauters JP, Wenger N, Whicombe H, Will EJ, Williams ME. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S1-290, 2004

68. Depner T, Daugirdas J, Greene T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek J, Levin N, Macon E, Milford E, Owen W, Star R, Toto R, Eknoyan G; Hemodialysis Study Group. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int 65(4):1386-94, 2004

69. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol 16:507-513, 2004

70. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT Jr, AASK Study Group. A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. J Am Soc Nephrol 15(12):3175-83, 2004

71. Toto RD. Lessons learned from recent clinical trials in hypertensive diabetics: what's good for the kidney is good for the heart and brain. Am J Hypertens 17(11 Pt 2):7S-10S, 2004

72. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens (Greenwich) 6(11 Suppl 3):2-7, 2004

73. Toto RD. Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int Suppl 92:S102-4, 2004

74. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24(4):453-60, 2004

18


75. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66(3):1131-8, 2004

76. Toto RD, Rinner S, Ram CV. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? Postgrad Med 116(2):11-6, 19-22, 48, 2004

77. Mohanram A, Zhang X, Shahnfar S, Keane W, Brenner B, Toto RD. Anemia and the risk of ESRD in Type 2 Diabetes with Nephropathy. Kidney Int 66:1131-8, 2004

78. Toto RD. Microalbuminuria: definition, detection, and clinical significance. J Clin Hypertens 6(Suppl 3):2-7, 2004

79. Bakris GL, Toto RD, McCullough PA. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens 19(2):139-44, 2005

80. Reddan D, Hasselblad V, Lowrie E, Szczech L, M.D., Lindsay R, Himmelfarb J, Toto RD, Stivelman J, Winchester JF, Zillman L, Califf, R., Owen, W. A trial of intradialytic blood volume monitoring in hemodialysis patients. JAMA, 2005 [epub ahead of print].

81. Tuttle K, Bakris G, Toto R, McGill J, Hu K, Anderson P. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care, 2005 [in press].

Invited Reviews:

1. Preisig PA, Toto RD, Alpern RJ. Carbonic anhydrase inhibitors. Renal Physiol Basel 10:136-159, 1987

2. Toto RD. Converting enzyme inhibitors treatment of hypertension and the kidney. AKF Newsletter 10:(4) 41-52, 1993

3. Toto RD, Vega GL, Grundy SM. Mechanisms and treatment of dyslipidemia of renal diseases. Curr Opin Hypertens Nephrol 2: 784-790, 1993

4. Toto RD, Mitchell HC, Pettinger WA. Treatment of hypertension in non-diabetic renal disease. Curr Opin Hypertens Nephrol 3:279-285, 1994

5. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and PAH. Curr Opin Hypertens Nephrol 4:505-509, 1995

6. Toto RD. Angiotensin-II receptor blockade: an innovative treatment for cardiovascular disease Postgrad Med November 1995

7. Toto RD. Angiotensin II receptor blockers and their role in the treatment of hypertension. Curr Nephrol Hypertens 19(7):218-225, 1996

Editorials and Book Chapters:

19


1. Alpern RJ, Toto RD. Hypokalemic nephropathy - A clue to cystogenesis? N Engl J Med 322:398-399, 1990

2. Toto RD. Assessing the evolution of atherosclerotic renal artery stenosis. Kidney Int 53(3):794-5, 1998

3. Toto RD. "Acute tubulointerstitial nephritis" in Clinical Nephrology 2nd edition, eds: Jacobson HR, Eknoyan G and Stryker GE. Williams and Wilkins 1996

4. Toto RD. "Metabolic derangements associated with diuretic use: Insulin resistance, dyslipidemia, hyperuricemia and antiandrogenic effects" in Diuretics, eds Seldin DW and Giebisch G. Raven Press 1998

5. Toto RD. "Acute tubulointerstitial nephritis caused by diuretics" in Diuretics, eds Seldin DW and Giebisch G. 1st Edition, Raven Press 1998

6. Toto RD. "Approach to treatment of mild hypertension." in Current Therapy in Nephrology and Hypertension. Mosby 1998

7. Toto RD. "Pharmacologic therapy of mild to moderate hypertension". R.J. Glassock, Editor. (4th Edition) Mosby 1998. Chapter: Hypertension - Current Therapy In Nephrology and Hypertension, pgs. 317-322

8. Toto RD. "Salt Wastage" in The Kidney: Physiology and Pathophysiology, 2nd Edition. eds Seldin DW and Giebisch G. New York, Raven Press. 1998

9. Toto RD. "Dyslipidemia in chronic renal failure" in Principles and Practice of Dialysis, ed. William N. Henrich. Williams and Wilkins 1998

10. Toto RD. "Approach to the patient with acute renal failure" in Nephrology Primer, National Kidney Foundation, 1998

11. Toto RD, Vega GL, Grundy GM. "Cholesterol management in patients with clinical renal disease". H.R. Brady & C.S. Wilcox (eds)., W.B. Saunders Company. Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney, Chapter 70, pgs. 491-496, 1999

12. Toto RD. "Salt Wastage", in The Kidney: Physiology and Pathophysiology, 3rd Edition. D.W. Seldin and G. Giebisch (eds). New York, Raven Press. 2002

13. Toto RD, Grundy S, Vega GL. "Treatment of dyslipidemia in chronic renal disease" in Companion to The Kidney, eds Wilcox C. and Brady H. 2nd Ed. Williams and Wilkins. 2003.

14. Toto RD. “Lipid lowering and progression of kidney disease” in The Kidney and Hypertension George Bakris (ed). Martin Dunitz, London England 2003.

15. Toto RD. “Dyslipidemia in dialysis patients” in Principles and Practice of Dialysis William Henrich (ed). Lippincott Williams and Wilkins Philadelphia, PA 2004.

20


16. Toto RD. "Approach to the Patient with Renal Disease" in The Kidney, ed Brenner and Rector. Williams and Wilkins 2004.

17. Mohanram A, and Toto RD. "Measurement of Renal Function" in Kidney Disease, ed Periera B and Levey A. 2004.

18. Toto RD. "Lipid lowering and progression of kidney disease" in The Kidney and Hypertension, ed Bakris. Martin Dunitz 2004.

19. Toto RD. "Hypertension in Chronic Kidney Disease" in Secondary Hypertension, ed Mansoor. Humana 2004.

20. Mohanram A, Toto RD. “Measurement of kidney function” in Chronic Kidney Disease, Dialysis, & Transplantation: A Companion to Brenner and Rector’s The Kidney Second Edition, eds B.J.G. Pereira, M.H. Sayegh and P Blake. Elsevier, Philadelphia, PA 2005

21

document

Documents

ut southwestern medical

medical education

present medical director

medical student class

presentmedical center

critical care medicine

outstanding teacher

present chief of nephrology